Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb/III randomized double-blind placebo-controlled study of icotrokinra in moderately to severely active Crohn's disease
CTR20254293Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of icotrokinra in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
icotrokinra
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20254293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254293.